Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial preparations.
OBJECTIVE
The aim of the present study was to test the feasibility of using commercial preparations of replacement and citrate anticoagulation solution in continuous venovenous haemofiltration (CVVH) in a safe, efficient and simple manner.


METHODS
Retrospective review of the database of a large continuous renal replacement therapy programme that uses a standardized prescription of high ultrafiltrate CVVH with commercial solutions for replacement fluid and regional citrate anticoagulation was performed.


RESULTS
Records of 28 patients who underwent 91 CVVH sessions were analysed. Median circuit survival time was 37 (59.5-15.5) h and the 48 h survival probability was 40%. Bleeding or metabolic complications were not noted, and the procedure was simple to administer.


CONCLUSIONS
Continuous venovenous haemofiltration using commercial preparations of replacement fluid and citrate anticoagulation can be safe, efficient and simple.
Munjal
Sandeep
S
Division of Nephrology, Hypertension and Transplantation, University of Florida, Gainesville, Florida 32610-0224, USA.
Ejaz
A Ahsan
AA
D058186:Acute Kidney Injury / Q000401:mortality / Q000628:therapy*; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D019343:Citric Acid / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000627:therapeutic use; D006440:Hemofiltration / Q000379:methods*; D006801:Humans; D007552:Isotonic Solutions; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate
D000925:Anticoagulants; D007552:Isotonic Solutions; D019343:Citric Acid; D005947:Glucose